Anticoagulant therapy with rivaroxaban in a young patient  with paroxysmal nocturnal hemoglobinuria.
The new direct oral anticoagulants such us rivaroxaban, could play an important role in the anticoagulant treatment of patients with paroxysmal nocturnal hemoglobinuria where anticoagulant treatment is complex to run, since they have shown a reduction in serious bleeding complications compared to antithrombotic therapy with classical vitamin k antagonist.
Thrombosis Center, Department of "Cellular Biotechnologies and Hematology", "Sapienza" University Rome, Italy.
Francesco
F
Dragoni
Department of "Biologia cellulare e Neuroscienze", Istituto Superiore di Sanità Rome, Italy.
Flavia
F
Chiarotti
Thrombosis Center, Department of "Cellular Biotechnologies and Hematology", "Sapienza" University Rome, Italy.
Laura
L
Lombardi
Thrombosis Center, Department of "Cellular Biotechnologies and Hematology", "Sapienza" University Rome, Italy.
Anna Paola
AP
Iori
Thrombosis Center, Department of "Cellular Biotechnologies and Hematology", "Sapienza" University Rome, Italy.
Arturo
A
Cafolla
Anticoagulant therapy; bleeding complication; paroxysmal nocturnal hemoglobinuria; rivaroxaban; thrombosis